Aptilon unveils new sales force tool

Share this article:
Aptilon announced the availability of an expanded set of tools that enables biopharmaceutical companies to increase access to valuable, high-prescribing physicians.

By combining new field-tested, rep-enabled tools with its established capabilities, Aptilon now offers biopharmaceutical sales representatives and medical science liaisons new and more effective ways to interact with hard-to-see physicians.

Aptilon's new services allow companies and their field reps to educate target physicians about their therapies, services and clinical research through five complementary options, including: remote live video details  that allows field sales to deliver Aptilon's AxcelRx live video detail sessions via their laptop or TabletPC from any location; call center live video details; self-guided activities; in-office contacts; and follow-up activities with new linkage tools including Aptilon's new Rep eMail capability enabling the field representative to send rapid, effective, personalized and regulatory-compliant follow-up emails to targeted physicians.

Whether a physician engaged with the company via an in-office detail or an Internet-based interaction, Aptilon's Rep eMail service allows for follow-up dialogue between the representative and the physician.

Each Rep eMail includes links that allow a physician to initiate an on-demand interaction with their rep at their convenience.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?